Candel Therapeutics, Inc. (CADL) Tops Q1 EPS by 20c

Candel Therapeutics, Inc. (NASDAQ: CADL) reported Q1 EPS of ($0.14), $0.20 better than the analyst estimate of ($0.34).

For earnings history and earnings-related data on Candel Therapeutics, Inc. (CADL) click here.

You May Also Be Interested In

• Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
• Franklin Covey (FC) Misses Q3 EPS by 2c, lowers Guidance
• Centrus Energy signs $900M DOE contract for uranium enrichment